Breaking News Instant updates and real-time market news.

CRIS

Curis

$3.22

-0.15 (-4.45%)

07:10
10/11/16
10/11
07:10
10/11/16
07:10

Curis expands pipeline with CA-327

Curis announced the expansion of its pipeline with CA-327, an oral, small molecule immune checkpoint antagonist targeting programmed death ligand-1, or PD-L1, and T-cell immunoglobulin and mucin domain containing protein-3, or TIM-3. Curis licensed the PD-1/ TIM-3 antagonist program, and designated CA-327 as the development candidate, by exercising its option under the collaboration, license and option agreement established with Aurigene in January 2015. The in-license of CA-327 comes three months after the collaboration's first oral immuno-oncology program entered the clinic and less than a month after a $24.5M investment in Curis by Aurigene.

CRIS Curis
$3.22

-0.15 (-4.45%)

03/01/16
RHCO
03/01/16
INITIATION
Target $3
RHCO
Buy
Curis initiated with a Buy at SunTrust
Target $3.
05/05/16
COWN
05/05/16
INITIATION
COWN
Outperform
Curis coverage assumed with an Outperform at Cowen

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.